MedTrace Logo

The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases

NCT01785316 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2024-01-26

No results posted yet for this study

Summary

A randomized controlled, open-label, multi-centre study evaluating if Isolated Hepatic Perfusion (IHP) increases Overall Survival compared with Best Alternative Care (BAC) in patients with isolated liver metastases from uveal melanoma.

Conditions

Interventions

PROCEDURE

IHP

Sponsors & Collaborators

  • Karolinska University Hospital

    collaborator OTHER

  • University Hospital, Linkoeping

    collaborator OTHER

  • Uppsala University Hospital

    collaborator OTHER

  • Skane University Hospital

    collaborator OTHER

  • University Hospital, Umeå

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Vastra Gotaland Region

    lead OTHER_GOV

Principal Investigators

  • Roger Olofsson Bagge, Dr · Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-15
Primary Completion
2023-03-15
Completion
2023-03-15

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01785316 on ClinicalTrials.gov